Current status of diagnostic and prognostic markers in melanoma

Methods in Molecular Biology

Volumn 1102, Issue , 2014, Pages 177-197

  Levine, Danielle ^a   Fisher, David E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomarker; Epigenetic; Melanoma; Prognosis; Proteomic

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CD146 ANTIGEN; CELL CYCLE PROTEIN; CYCLINE; CYSTEINYLDOPA; DOPA; FIBROBLAST GROWTH FACTOR 2; GALECTIN 3; GELATINASE A; GLYCOPROTEIN GP 100; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MACROPHAGE INFLAMMATORY PROTEIN; MATRIX METALLOPROTEINASE; MELAN A; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN S100B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TYROSINE; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; DESORPTION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; MELANOMA CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME OF FLIGHT MASS SPECTROMETRY; TISSUE MICROARRAY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

HUMANS; MELANINS; MELANOMA; NEOPLASM PROTEINS; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891790713     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-727-3_11     Document Type: Article

References (89)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Ak I, Stokkel MP, Bergman W, Pauwels EK (2000) Cutaneous malignant melanoma: Clinical aspects, imaging modalities and treatment. Eur J Nucl Med 27:447-458
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206
4. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U et al (2007) Evidence and interdisciplinary consensebased German guidelines: Diagnosis and surveillance of melanoma. Melanoma Res 17:393-399
5. Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N et al (2002) UK guidelines for the management of cutaneous melanoma. Br J Plast Surg 55:46-54
6. Dummer R, Hauschild A (2008) Jost L Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii86-ii88
7. Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M, Soong SJ et al (2008) Follow-up schedules after treatment for malignant melanoma. Br J Surg 95:1401-1407
8. Sabel MS, Liu Y, Lubman DM (2011) Proteomics in melanoma biomarker discovery: Great potential, many obstacles. Int J Proteomics 2011:181890
9. Shi SR, Liu C, Taylor CR (2007) Standardization of immunohistochemistry for formalin-fixed, paraffi n-embedded tissue sections based on the antigen-retrieval technique: From experiments to hypothesis. J Histochem Cytochem 55(2):105-109
10. Coons AH (1791) The development of immunohistochemistry. NY Acad Sci 177:5-9
11. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844-847
12. Battifora H, Skacel M, Skilton B, Pettay JD, Tubbs RR (2002) Tissue microarrays: A powerful tool for high-throughput analysis of clinical specimens. Appl Immunohistochem Mol Morphol 10:1-6
13. Horne BD, Carlquist JF, Cannon-Albright LA, Muhlestein JB, McKinney JT, Kolek MJ, Clarke JL, Anderson JL, Camp NJ (2006) High-resolution characterization of linkage disequilibrium structure and selection of tagging single nucleotide polymorphisms: Application to the cholesteryl ester transfer protein gene. Ann Hum Genet 70(Pt 4):524-534
14. Marvin LF, Roberts MA, Fay LB (2003) Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry. Clin Chim Acta 337(1-2):11-21
15. de Vries TJ, Smeets M, de Graaf R, Hou-Jensen K, Bröcker EB, Renard N, Eggermont AM, van Muijen GN, Ruiter DJ (2001) Expression of gp100, MART-1, tyrosinase, and S100 in paraffi n-embedded primary melanomas and locoregional, lymph node, and visceral metastases: Implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 193(1):13-20
16. Utikal J, Schadendorf D, Ugurel S (2007) Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res 298(10):469-477
17. Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R (2009) Biomarkers in melanoma. Ann Oncol 20(Suppl 6):vi8-vi13
18. Liu S, Kirschmeier P, Simon J, Seidel-Dugan C, Puhlmann M (2008) Prognostic and predictive molecular markers in cutaneous malignant melanoma: The fi rst step toward personalized medicine. Curr Pharmacogenomics Person Med 6(4):272-294
19. Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, Näher H (1999) S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17(6):1891-1896
20. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A, Martin L, Martini MC, Pruitt SK, Ross MI, Sener SF, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, Weber J, Wong MK, NCCN melanoma panel (2009) Melanoma. J Natl Compr Canc Netw 7(3):250-275
21. Thompson JF, Shaw HM, Stretch JR, McCarthy WH, Milton GW (2003) The Sydney melanoma unit -A multidisciplinary melanoma treatment center. Surg Clin North Am 83(2):431-451
22. Deichmann M, Kahle B, Moser K, Wacker J, Wüst K (2004) Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 91(4):699-702
23. Moore Dalal K, Zhou Q, Panageas KS, Brady MS, Jaques DP, Coit DG (2008) Methods of detection of fi rst recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 15(8):2206-2214
24. Lin J, Yang Q, Wilder PT, Carrier F, Weber DJ (2010) The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem 285(35): 27487-27498
25. Kruijff S, Hoekstra HJ (2012) The current status of S-100B as a biomarker in melanoma. Eur J Surg Oncol 38(4):281-285
26. Bouwhuis MG, Suciu S, Kruit W, Salès F, Stoitchkov K, Patel P, Cocquyt V, Thomas J, Liénard D, Eggermont AM, Ghanem G (2011) Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952. European Organisation for Research and Treatment of Cancer Melanoma Group. Eur J Cancer 47(3):361-368
27. Vereecken P, Cornelis F, Van Baren N, Vandersleyen V, Baurain JF (2012) A synopsis of serum biomarkers in cutaneous melanoma patients. Dermatol Res Pract 2012:260643
28. Dummer R, Panizzon R, Bloch PH, Burg G (2005) Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 210(1):39-44
29. Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R, Hauschild A (2008) Short German guidelines: Malignant melanoma. J Dtsch Dermatol Ges 6(Suppl 1):S9-S14
30. Retsas S, Mastrangelo MJ (2007) Refl ecting on the 2001 American Joint Committee on Cancer Staging System for melanoma. Semin Oncol 34(6):491-497
31. Vihinen PP, Hilli J, Vuoristo MS, Syrjänen KJ, Kähäri VM, Pyrhönen SO (2007) Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol 46(5):678-684
32. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13(8):2422-2428
33. Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM (2010) Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 41(3):375-384, Epub 2009 Dec 11
34. Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Comessatti MG (2002) VEGF-165 serum levels and tyrosinase expression in melanoma patients: Correlation with the clinical course. Melanoma Res 12(4):325-334
35. Väisänen A, Kuvaja P, Kallioinen M, Turpeenniemi-Hujanen T (2011) A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum Pathol 42(8):1103-1111
36. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R (2011) Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 17(8):2417-2425
37. Bu W, Tang ZY, Sun FX, Ye SL, Liu KD, Xue Q, Chen J, Gao DM (1998) Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogastroenterology 45(22):1056-1061
38. Rey MC, Bonamigo RR, Cartell A, Furian R, Bonfá R, Bonfá R (2011) MMP-2 and TIMP-2 in cutaneous melanoma: Association with prognostic factors and description in cutaneous metastases. Am J Dermatopathol 33(4):413-414
39. Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C (2002) Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol 197(2): 179-187
40. Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D (2000) Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 20(3B):2203-2207
41. Bougatef F, Menashi S, Khayati F, Naïmi B, Porcher R, Podgorniak MP, Millot G, Janin A, Calvo F, Lebbé C, Mourah S (2010) EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2. PLoS One 5(8):e12265
42. Kanekura T, Chen X (2010) CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 57(3): 149-154
43. van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C (1997) Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 151(3):665-670
44. Wang YG, Kim SJ, Baek JH, Lee HW, Jeong SY, Chun KH (2012) Galectin-3 increases the motility of mouse melanoma cells by regulating MMP-1 expression. Exp Mol Med 44(6): 387-393
45. Chen T, Zhu J (2010) Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol 27(4):1185-1191
46. Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion-Sileni V, Picozzo J, Romanini A, Nanni O, Ridolfi R, Italian Melanoma Intergroup (IMI) (2006) Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Res 16(4):317-323
47. Boyano MD, Garcia-Vázquez MD, López-Michelena T, Gardeazabal J, Bilbao J, Cañavate ML, Galdeano AG, Izu R, Díaz-Ramón L, Raton JA, Díaz-Pérez JL (2000) Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 83(7): 847-852
48. Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E, Kellokumpu-Lehtinen P (2001) Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 37(13):1629-1634
49. Alonso SR, Ortiz P, Pollán M, Pérez-Gómez B, Sánchez L, Acuña MJ, Pajares R, Martínez-Tello FJ, Hortelano CM, Piris MA, Rodríguez-Peralto JL (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profi les: A tissue microarray-based study. Am J Pathol 164(1):193-203
50. de Souza CF, Morais AS, Jasiulionis MG (2012) Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract 2012:156068. Epub 2011 Oct 31
51. Gould Rothberg BE, Bracken MB, Rimm DL (2009) Tissue biomarkers for prognosis in cutaneous melanoma: A systematic review and metaanalysis. J Natl Cancer Inst 101(7):452-474
52. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001) Cyclin A expression in superfi cial spreading malignant melanomas correlates with clinical outcome. J Pathol 195(5):530-536
53. Niezabitowski A, Czajecki K, Rys J (1999) Prognostic evaluation of cutaneous malignant melanoma: A clinicopathologic and immunohistochemical study. J Surg Oncol 70(3): 150-160
54. Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM, Woolf EA, Tepper RI, Shyjan AW (1998) Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 58:1515
55. Deeds J, Cronin F, Duncan LM (2000) Patterns of melastatin mRNA expression in melanocytic tumors. Hum Pathol 31:1346
56. Erickson LA, Letts GA, Shah SM, Shackelton JB, Duncan LM (2009) TRPM1 (Melastatin-1/ MLSN1) mRNA expression in Spitz nevi and nodular melanomas. Mod Pathol 22(7): 969-976
57. Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, McCarthy JJ (2001) Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 19:568-576
58. Miller AJ, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE (2004) Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res 64:509
59. Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R, Steingrimsson E (2008) Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 21:665
60. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplifi ed in malignant melanoma. Nature 436:117-122
61. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, Fisher DE (2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6:565-576
62. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O'Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99-103
63. Flaherty KT, Hodi FS, Fisher DE (2012) From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer 12(5):349-361
64. Hillesheim PB, Slone S, Kelley D, Malone J, Bahrami S (2011) An immunohistochemical comparison between MiTF and MART-1 with Azure blue counterstaining in the setting of solar lentigo and melanoma in situ. J Cutan Pathol 38(7):565-569
65. Nielsen PS, Riber-Hansen R, Steiniche T (2011) Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: Promising diagnostic tools in melanocytic lesions. Am J Dermatopathol 33(4):361-370
66. Samija I, Lukac J, Marić-Brozić J, Buljan M, Alajbeg I, Kovacević D, Situm M, Kusić Z (2010) Prognostic value of microphthalmiaassociated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Res 20(4):293-302
67. Bosserhoff AK, Hein R, Bogdahn U, Buettner R (1996) Structure and promoter analysis of the gene encoding the human melanomainhibiting protein MIA. J Biol Chem 271(1):490-495
68. Garnier JP, Letellier S, Cassinat B, Lebbé C, Kerob D, Baccard M, Morel P, Basset-Seguin N, Dubertret L, Bousquet B, Stoitchkov K, Le Bricon T (2007) Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 43(4):816-821
69. Díaz-Lagares A, Alegre E, Arroyo A, González-Cao M, Zudaire ME, Viteri S, Martín-Algarra S, González A (2011) Evaluation of multiple serum markers in advanced melanoma. Tumour Biol 32(6):1155-1161
70. Nakahara S, Oka N, Raz A (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10(2):267-275
71. Brown ER, Doig T, Anderson N, Brenn T, Doherty V, Xu Y, Bartlett JM, Smyth JF, Melton DW (2012) Association of galectin-3 expression with melanoma progression and prognosis. Eur J Cancer 48(6):865-874
72. Buljan M, Šitum M, Tomas D, Milošević M, Krušlin B (2011) Prognostic value of galectin-3 in primary cutaneous melanoma. J Eur Acad Dermatol Venereol 25(10):1174-1181
73. Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M (2008) Osteopontin as a molecular prognostic marker for melanoma. Cancer 112(1):144-150
74. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20(1):102-107
75. Ebrahimnejad A, Streichert T, Nollau P, Horst AK, Wagener C, Bamberger AM, Brümmer J (2004) CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol 165(5):1781-1787
76. Thies A, Moll I, Berger J, Wagener C, Brümmer J, Schulze HJ, Brunner G, Schumacher U (2002) CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 20(10):2530-2536
77. Watson-Hurst K, Becker D (2006) The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther 5(10):1375-1382
78. Pacifi co MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson G (2005) Development of a tissue array for primary melanoma with longterm follow-up: Discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 115(2):367-375
79. Kärnell R, Kågedal B, Lindholm C, Nilsson B, Arstrand K, Ringborg U (2000) The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res 10(4): 363-369
80. Kvam E, Dahle J (2005) The pheomelanin precursor 5-S-cysteinyldopa protects melanocytes from membrane damage induced by ultraviolet A radiation. Cancer Lett 221(2):131-134
81. Bánfalvi T, Boldizsár M, Gergye M, Gilde K, Kremmer T, Ottó S (2002) Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma. Pathol Oncol Res 8(3):183-187
82. Slominski A, Zmijewski MA, Pawelek J (2012) L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res 25(1): 14-27
83. Abaffy T, Duncan R, Riemer DD, Tietje O, Elgart G, Milikowski C, DeFazio RA (2010) Differential volatile signatures from skin, naevi and melanoma: A novel approach to detect a pathological process. PLoS One 5(11):e13813
84. Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS (2012) Epigenetic biomarkers in skin cancer. Cancer Lett 85
85. Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL, Hoon DS (2011) Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 6(3):388-394
86. McShane LM, Altman DG, Gion M, Clark GM, Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235
87. Schramm SJ, Mann GJ (2011) Melanoma prognosis: A REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther 10(8):1520-1528, Epub 2011 Jun 9. Review
88. Pras F, Perra MT, Murtas D, Minerba L, Floris C, Maxia C (2008) Combinations of apoptosis and cell-cycle control biomarkers predict the outcome of human melanoma. Oncol Rep 20:271-277
89. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F (2009) A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15: 6987-6992